Literature DB >> 33634983

A folate receptor 3 SNP promotes mitochondria-induced clonogenicity of CML leukemia cells: Implications for treatment free remission.

Na Shen1,2, Teng Liu3, Wen Liu4, Zhaodong Zhong4, Qing Li5, Xiaoying Zhu4, Ping Zou4, Yong You4, An-Yuan Guo3, Xiaojian Zhu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33634983      PMCID： PMC7862584          DOI： 10.1002/ctm2.317

Source DB:  PubMed          Journal:  Clin Transl Med        ISSN： 2001-1326


× No keyword cloud information.
  9 in total

1.  Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

Authors:  Gabriel Etienne; Joëlle Guilhot; Delphine Rea; Françoise Rigal-Huguet; Franck Nicolini; Aude Charbonnier; Agnès Guerci-Bresler; Laurence Legros; Bruno Varet; Martine Gardembas; Viviane Dubruille; Michel Tulliez; Marie-Pierre Noel; Jean-Christophe Ianotto; Bruno Villemagne; Martin Carré; François Guilhot; Philippe Rousselot; François-Xavier Mahon
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

2.  In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.

Authors:  Lucy C Crossman; Motomi Mori; Yi-Ching Hsieh; Thoralf Lange; Peter Paschka; Christina A Harrington; Knut Krohn; Dietger W Niederwieser; Rüdiger Hehlmann; Andreas Hochhaus; Brian J Druker; Michael W N Deininger
Journal:  Haematologica       Date:  2005-04       Impact factor: 9.941

3.  A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.

Authors:  Shannon K McWeeney; Lucy C Pemberton; Marc M Loriaux; Kristina Vartanian; Stephanie G Willis; Gregory Yochum; Beth Wilmot; Yaron Turpaz; Raji Pillai; Brian J Druker; Jennifer L Snead; Mary MacPartlin; Stephen G O'Brien; Junia V Melo; Thoralf Lange; Christina A Harrington; Michael W N Deininger
Journal:  Blood       Date:  2009-10-16       Impact factor: 22.113

4.  Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs.

Authors:  Giora Sharf; Celia Marin; Jennifer A Bradley; Zack Pemberton-Whiteley; Felice Bombaci; Rita I O Christensen; Bahija Gouimi; Nigel B Deekes; Mina Daban; Jan Geissler
Journal:  Leukemia       Date:  2020-05-26       Impact factor: 11.528

5.  The Telomerase Complex Directly Controls Hematopoietic Stem Cell Differentiation and Senescence in an Induced Pluripotent Stem Cell Model of Telomeropathy.

Authors:  Shyam Sushama Jose; Federico Tidu; Petra Burilova; Tomas Kepak; Kamila Bendickova; Jan Fric
Journal:  Front Genet       Date:  2018-08-29       Impact factor: 4.599

6.  Mitochondrial translation requires folate-dependent tRNA methylation.

Authors:  Raphael J Morscher; Gregory S Ducker; Sophia Hsin-Jung Li; Johannes A Mayer; Zemer Gitai; Wolfgang Sperl; Joshua D Rabinowitz
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

7.  ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy.

Authors:  Ya-Ru Miao; Qiong Zhang; Qian Lei; Mei Luo; Gui-Yan Xie; Hongxiang Wang; An-Yuan Guo
Journal:  Adv Sci (Weinh)       Date:  2020-02-11       Impact factor: 16.806

8.  Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.

Authors:  Takashi Kumagai; Chiaki Nakaseko; Kaichi Nishiwaki; Chikashi Yoshida; Kazuteru Ohashi; Naoki Takezako; Hina Takano; Yasuji Kouzai; Tadashi Murase; Kosei Matsue; Satoshi Morita; Junichi Sakamoto; Hisashi Wakita; Hisashi Sakamaki; Koiti Inokuchi
Journal:  Cancer Sci       Date:  2017-11-29       Impact factor: 6.716

9.  Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?

Authors:  Ehab Atallah; Charles A Schiffer
Journal:  Haematologica       Date:  2020-12-01       Impact factor: 9.941
  9 in total
  1 in total

Review 1.  Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission.

Authors:  Ruth Stuckey; Juan Francisco López Rodríguez; María Teresa Gómez-Casares
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.075
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.